Why the NHS Won’t Pay for the PSE (phi) Test – Even Though It Could Save Thousands of Men from Unnecessary Biopsies

If you’re a man over 50 in the UK and your GP tells you your PSA is raised, the next words you’ll probably hear are: “We need to refer you to urology for possible biopsy.”
Every year this happens to around 100,000 British men. Up to 70% of them will turn out NOT to have prostate cancer, or only have a slow-growing type that would never have harmed them. They still undergo an unpleasant (and risky) trans-rectal biopsy, worry themselves sick, and some end up with sepsis or erectile problems.

There is a simple blood test that can prevent a large proportion of these unnecessary biopsies. It’s called the Prostate Health Index, or phi (sometimes referred to as the PSE test in older literature). In head-to-head studies it outperforms everything else we currently have – including total PSA, free PSA percentage, and even MRI in some scenarios – when it comes to ruling out the need for biopsy.

So why doesn’t the NHS routinely offer it?

How much better is phi than PSA alone?

• In men with a PSA between 2–10 ng/mL (the grey zone where most false positives live), phi reduces unnecessary biopsies by 25–40% while missing almost no aggressive cancers.
• A major European trial showed that using phi as a reflex test would have safely avoided 42% of biopsies in the UK screening setting.
• The risk of high-grade cancer at phi scores <25 is around 1% – lower than many men’s risk after a “normal” MRI.

The NHS position (as of 2025)

NICE (National Institute for Health and Care Excellence) has looked at phi twice – in 2015 and again in 2022 – and both times decided not to recommend it for routine NHS use. The main reasons given:

1. Cost-effectiveness threshold not quite met
   The test costs the lab about £90–£120 (compared with £10–15 for a standard PSA). NICE’s modelling said the QALY (quality-adjusted life year) gain was just below their usual willingness-to-pay threshold.
2. MRI has taken centre stage
   Since 2019, NICE has pushed pre-biopsy multiparametric MRI as the main gatekeeper. MRI is excellent, but it is expensive (£400–£800), takes 30–45 minutes of scanner time, needs a radiologist report, and still misses or overcalls some cancers. Phi is a £100 blood test that can be done the same day in primary care and often makes the MRI unnecessary.
3. Lack of a randomised UK trial
   Most of the big phi studies come from Europe and the USA. NICE likes evidence generated in (or at least directly applicable to) the NHS setting.

The private sector reality

Walk into almost any private urology clinic in London, Manchester or Glasgow and if your PSA is 3–12, they will offer you phi (or the similar 4Kscore) before rushing you to MRI or biopsy. Many men happily pay £200–£300 to avoid the anxiety and side effects.

What the numbers really look like in 2025

• ~100,000 men per year in the UK get referred for suspected prostate cancer
• ~75,000 end up having a biopsy
• ~55,000 of those biopsies are negative or find harmless cancer
• If phi were used reflexively, ~20–30,000 of those biopsies could be safely avoided every year
• Serious sepsis from biopsy: ~2–3% → that’s 1,500–2,000 fewer hospital admissions
• Cost of one episode of biopsy-related sepsis: £5,000–£15,000

Even with conservative assumptions, many health economists (outside NICE) now believe phi + selective MRI would save the NHS money overall.

The bottom line for UK men right now

• The NHS will continue to rely on PSA → MRI → biopsy pathway.
• You can ask your GP for a phi test, but they almost certainly cannot order it on the NHS.
• If you have private medical insurance or are willing to pay £150–£300 out of pocket, the test is widely available at Spire, Nuffield, HCA, and many independent urology groups.
• A phi score <25 with a normal digital rectal exam is extremely reassuring – most urologists would then watch and repeat PSA in 12–24 months rather than rush to MRI or biopsy.

Final thought

The UK led the world in showing that PSA screening causes over-treatment (the ProtecT and CAP trials). We now have a tool that dramatically reduces that harm, yet the system hasn’t caught up. Until NICE re-evaluates or a UK-specific trial is funded, the PSE/phi test remains one of the clearest examples of a better technology being available – just not on the NHS.

If your PSA is raised and you want to avoid an unnecessary biopsy, it’s worth knowing the option exists – even if you have to pay for it yourself.